Digital Health
99 VCs and 35 funds investing in Digital Health
VCs investing in Digital Health
Bryan Rosenblatt
Venture Partner
Craft Ventures
Check: No personal check-size range is published. Craft invests from angel/seed through venture and growth; amounts in Bryan's investment announcements are total company rounds, not his personal or standard Craft checks.
Bryan applies a growth, revenue, and marketplace lens shaped by building Reddit's New York revenue organization and Twitter's startup advertising business. His investments favor products that remove expensive operational friction, demonstrate clear founder-market fit, delight customers enough to produce strong advocacy, and can use software, AI, services, or community-led distribution to create a meaningful performance advantage.
Alex Morgan
Partner
Khosla Ventures
Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.
Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.
Jun Wakabayashi
Venture Principal
AppWorks
Check: Not publicly disclosed for Beacon Funds commitments. AppWorks' direct-company strategy publishes US$200K to US$15M per deal from Seed through Series C; that range should not be applied to Jun's venture-fund investments.
Jun uses fund investments as ecosystem infrastructure: back locally connected or specialist managers, exchange market intelligence and diligence, create co-investment and follow-on capital paths, and help portfolio companies enter new Asian markets. In direct opportunities, his writing favors repeat founders with learned resilience, large problems native to Southeast Asia, sound unit economics, profitability and margin discipline, and teams able to adapt when the original model fails.
Arielle Rothman
Investor
BoxGroup
Check: No reliable Arielle-specific check size is public. BoxGroup describes itself as an earliest-stage investor, but founders should confirm current round fit and allocation directly rather than relying on third-party range estimates.
Arielle invests within BoxGroup's broad earliest-stage mandate. Her differentiated documented context is technical and translational: Harvard bioengineering research, founding a postpartum medical-device project, product work in fertility AI and neuromodulation, mechanical engineering at a bioelectronic-medicine startup, and consulting at BCG. This supports a credible ability to evaluate user need, clinical workflow, product design, manufacturing, regulatory planning and commercialization in technical health businesses. It does not establish an exclusive healthcare mandate or a personally published investment thesis.
Jackie Vullinghs
Partner
AirTree Ventures (Web3)
Check: Neither Airtree nor Jackie publishes her personal check range or decision authority. The firm is seed-first and supports companies through later stages; individual portfolio round totals do not reveal Airtree's allocation or Jackie's authority.
Jackie backs Australia and New Zealand founders from very early product formation through scale. Her disclosed portfolio crosses AI and enterprise software, healthcare, fintech, consumer platforms, future-of-work tools, commerce, and purpose-led brands. Her investment notes repeatedly test market size and structural change, founder intensity and fit, customer love, defensible unit economics, resilience, and the ability to convert an initial wedge into a global company.
Fanis Tsarouchis
Senior Principal
Big Pi Ventures
Check: Growth-fund level: Big Pi Growth I states that it leads with €7M–€20M+ per company. Big Pi's overall platform spans €0.5M–€30M across funds. Neither range is published as Fanis's personal allocation authority.
Fanis supports European technology scale-ups moving toward market leadership with growth capital plus operational and financial expertise. His background in TMT investment banking and as FlexCar's finance leader supports a value-creation lens centered on financing structure, valuation, capital efficiency, international expansion, organic growth, and selective M&A rather than capital alone.
Wendy Xiao
Partner
Northzone (Web3)
Check: Not publicly disclosed. Northzone states that the firm invests from Seed through Growth and can remain a partner through pre-IPO; Wendy's current profile labels her personal focus as Early and says she likes to work with founders from as early as seed.
Wendy backs companies that change consumer behavior and expand the economic pie by capturing neglected externalities. She studies technology through people and behavior change, looking for a valuable position in a shifting value chain and a product capable of profound systemic change. Her hypothesis-led process separates factual and emotional evidence, makes assumptions explicit, challenges them through diligence, and still requires a differentiated leap of faith about fund-returning potential.
Panos Metsis
Partner
Big Pi Ventures
Check: Growth-fund level: Big Pi Growth I states that it leads with €7M–€20M+ per company. Panos focuses on Series B+ growth investments; the published fund range is not a guarantee of his personal allocation authority for any deal.
Panos leads growth investments in European technology companies that already show category leadership and can use €7M–€20M+ plus active operating support to scale internationally. His recent work emphasizes InfraTech and Physical AI at the intersection of innovative technology and real infrastructure, where proprietary systems, strong customer ROI, global deployments, and Southeast European operating hubs can create durable scale advantages.
Shelly Lanning
Venture Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Shelly Lanning invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Jenni Le
Principal
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Jenni Le invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
John Neis
Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
John Neis invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Joslin Owens
Director of Finance
7wire Ventures
Check: 7wire Ventures does not publish a standard current check-size range on its official site.
Joslin Owens is listed in a Director of Finance capacity at 7wire Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Cheryl R. Blanchard, PhD
Executive in Residence
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Cheryl R. Blanchard, PhD invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Margaret Kaczor Andrew
Venture Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Margaret Kaczor Andrew invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Becky Hoerman
Controller
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Becky Hoerman is listed in a Controller capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Ravi Varma
Venture Partner
Tau Ventures
Check: Tau Ventures does not publish a standard current check-size range on its live official site.
Ravi Varma invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.
Gary Ang
Venture Partner
Tau Ventures
Check: Tau Ventures does not publish a standard current check-size range on its live official site.
Gary Ang invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.
Sharon Huang
Principal
Tau Ventures
Check: Tau Ventures does not publish a standard current check-size range on its live official site.
Sharon Huang invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.
Larry Augustin
Venture Partner
Tau Ventures
Check: Tau Ventures does not publish a standard current check-size range on its live official site.
Larry Augustin invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.
Bruce Broussard
Venture Partner
Define Ventures
Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.
Bruce Broussard invests or supports investments through Define Ventures's published strategy: Back category-defining healthcare companies that combine deep ecosystem understanding with a technology-driven mindset across enterprise, value-based care and consumer health.
David Schonthal
Operating Partner
7wire Ventures
Check: 7wire Ventures does not publish a standard current check-size range on its official site.
David Schonthal is listed in a Operating Partner capacity at 7wire Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Scott Button
Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Scott Button invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
David Arnstein
Partner and Chief Financial Officer
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
David Arnstein is listed in a Partner and Chief Financial Officer capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Karsten Vagner
Head of People
Define Ventures
Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.
Karsten Vagner is listed in a Head of People capacity at Define Ventures. This profile preserves that functional distinction; the firm's investment mandate is included only as shared context.
Joe Amaral, MD
Chief Medical and Scientific Officer
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Joe Amaral, MD is listed in a Chief Medical and Scientific Officer capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Katharine Morris
Administrative Assistant & Office Manager
Define Ventures
Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.
Katharine Morris is listed in a Administrative Assistant & Office Manager capacity at Define Ventures. This profile preserves that functional distinction; the firm's investment mandate is included only as shared context.
Sathya Shanthakumar
Director of Investor Relations
7wire Ventures
Check: 7wire Ventures does not publish a standard current check-size range on its official site.
Sathya Shanthakumar is listed in a Director of Investor Relations capacity at 7wire Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Vivek Ranadivé
Founder and Managing Director
Bow Capital
Check: $5M average investment into core companies, as published by Bow Capital.
Vivek Ranadivé is listed in a Founder and Managing Director capacity at Bow Capital. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Disha Karale
Investor
BoxGroup
Check: BoxGroup publicly invests up to $1M. Third-party profiles estimate Disha's range at $500K–$1M, but no primary source confirms a personal range, so the firm ceiling is the safer planning assumption.
Disha invests at the earliest stages with a differentiated mix of finance, neuroscience, biotech R&D, and prior growth-investing exposure. Her public investor profile points to AI, enterprise infrastructure and software, digital and consumer health, biotech, and commerce. Within BoxGroup's generalist model, the through-line is an exceptional founder using technical or domain insight to create a category, not a rigid sector checklist.
Sonal Panda
Advisory Partner
Tau Ventures
Check: Tau Ventures does not publish a standard current check-size range on its live official site.
Sonal Panda is listed in a Advisory Partner capacity at Tau Ventures. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Amit Garg
Founding Partner
Tau Ventures
Check: Tau Ventures does not publish a standard current check-size range on its live official site.
Amit Garg invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.
Emma Merrick
Associate
HealthX Ventures
Check: HealthX Ventures does not publish a standard check-size range on its current official website.
Emma Merrick contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.
Fahad Qureshi
Vice President, Accounting and Finance
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Fahad Qureshi is listed in a Vice President, Accounting and Finance capacity at OCA Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Dan Neill
Venture Consultant
HealthX Ventures
Check: HealthX Ventures does not publish a standard check-size range on its current official website.
Dan Neill contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.
Sanjay Rao
Founding Partner
Tau Ventures
Check: Tau Ventures does not publish a standard current check-size range on its live official site.
Sanjay Rao invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.
Adina Davis
Partner
BoxGroup
Check: BoxGroup publicly invests up to $1M. Older third-party profiles place Adina's typical early-stage range around $250K–$500K, but founders should treat the firm's current $1M ceiling—not an old personal range—as authoritative.
Adina is an early-stage generalist with a publicly documented emphasis on B2B software, consumer internet, and fintech. Her operating background in e-commerce and recent visible interest in AI deployment and software agents point to companies that convert new technical capability into practical workflows. She invests within BoxGroup's people-first formation-stage model, prioritizing founder-market fit and category potential over polished early metrics.
Sam Bogrov
Principal
Tau Ventures
Check: Tau Ventures does not publish a standard current check-size range on its live official site.
Sam Bogrov invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.
Stefano Guidotti
Partner
P101
Check: P101 does not publish one standard current check-size range on its official site.
Stefano Guidotti invests or supports investment work through P101. P101's published strategy is to partner early and for the long term with bold, resilient founders building technology companies that can matter internationally..
Laura Hilty
Principal
HealthX Ventures
Check: HealthX Ventures does not publish a standard check-size range on its current official website.
Laura Hilty contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.
Roy Rosin
Board Partner
First Round Capital
Check: Firm-level: First Round says initial investments typically range from $1M-$7M, average about $3.5M, and have ranged below and above that; participating rounds have ranged from $100K-$20M.
Roy spends most of his First Round time in healthcare, applying three decades of product, innovation, and care-delivery experience to companies that can materially improve lives. He favors practical experimentation and measurable implementation over technology theater: identify a consequential workflow, build with the private context and orchestration required for accuracy, rigorously test real outcomes, and help founders win early customers, prioritize development, refine sales, hire, and learn faster.
Lynne Chou O'Keefe
Founder & Managing Partner
Define Ventures
Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.
Lynne Chou O'Keefe invests or supports investments through Define Ventures's published strategy: Back category-defining healthcare companies that combine deep ecosystem understanding with a technology-driven mindset across enterprise, value-based care and consumer health.
Tejas Vijh
Associate
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Tejas Vijh invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Frank Williams
Venture Partner
Define Ventures
Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.
Frank Williams invests or supports investments through Define Ventures's published strategy: Back category-defining healthcare companies that combine deep ecosystem understanding with a technology-driven mindset across enterprise, value-based care and consumer health.
Carolyn Magill
Venture Partner
Define Ventures
Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.
Carolyn Magill invests or supports investments through Define Ventures's published strategy: Back category-defining healthcare companies that combine deep ecosystem understanding with a technology-driven mindset across enterprise, value-based care and consumer health.
Tom Richards
Operating Partner
7wire Ventures
Check: 7wire Ventures does not publish a standard current check-size range on its official site.
Tom Richards is listed in a Operating Partner capacity at 7wire Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Liz Todia Zambory
Principal
Mutual Capital Partners
Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.
Liz Todia Zambory invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.
Alexis Johnson
Chief of Staff
HealthX Ventures
Check: HealthX Ventures does not publish a standard check-size range on its current official website.
Alexis Johnson contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.
Claire Smilow
Partner
BoxGroup
Check: BoxGroup publicly invests up to $1M. Some third-party directories show an older $250K–$500K personal range, but no current primary source confirms a separate personal allocation.
Claire backs formation-stage technology companies as a BoxGroup generalist, with visible strength across enterprise and developer software, AI-native products, consumer experiences, and marketplaces. Her operating and investing background supports a product-and-distribution lens: founders should pair a distinctive experience with a credible route to repeated use and category leadership, even when the company is still pre-product or pre-traction.
Paul Weiss
Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Paul Weiss invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Brian Lindstrom
Partner
HealthX Ventures
Check: HealthX Ventures does not publish a standard check-size range on its current official website.
Brian Lindstrom contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.
Shannon Knous
VP of Finance & Operations
Define Ventures
Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.
Shannon Knous is listed in a VP of Finance & Operations capacity at Define Ventures. This profile preserves that functional distinction; the firm's investment mandate is included only as shared context.
Lauren O'Mahony
Head of Marketing
Define Ventures
Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.
Lauren O'Mahony is listed in a Head of Marketing capacity at Define Ventures. This profile preserves that functional distinction; the firm's investment mandate is included only as shared context.
Cameron Raglin
Senior Associate
7wire Ventures
Check: 7wire Ventures does not publish a standard current check-size range on its official site.
Cameron Raglin invests or supports investments through 7wire Ventures's published strategy: Build and back early-stage digital-health companies that give informed, connected consumers more control and improve healthcare quality, access, outcomes and cost.
Allison Weiland
Finance and Operations Manager
Tamarind Hill
Check: $2M-$7M seed rounds, as published by Tamarind Hill.
Allison Weiland is listed in a Finance and Operations Manager capacity at Tamarind Hill. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Glenda Grazioli
Partner
P101
Check: P101 does not publish one standard current check-size range on its official site.
Glenda Grazioli invests or supports investment work through P101. P101's published strategy is to partner early and for the long term with bold, resilient founders building technology companies that can matter internationally..
Alex Shandiz
General Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Alex Shandiz invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Ariel MacTavish
Venture Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Ariel MacTavish invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Audrey Beckman
Partner and Chief Innovation Officer
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Audrey Beckman invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Dick Aderman
Studio Director
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Dick Aderman is listed in a Studio Director capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Oscar Moralez
Founder and Managing Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Oscar Moralez invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Todd R. Lugar
Controller and HR Lead
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Todd R. Lugar is listed in a Controller and HR Lead capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Shannon Flaherty
VP, Operations & Compliance
HealthX Ventures
Check: HealthX Ventures does not publish a standard check-size range on its current official website.
Shannon Flaherty contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.
Christie Currie
Senior Associate
Tamarind Hill
Check: $2M-$7M seed rounds, as published by Tamarind Hill.
Christie Currie invests or supports investments through Tamarind Hill's published strategy: Lead seed rounds for B2B healthcare companies with early product-market fit across decentralized care, care economics and healthcare supply-chain innovation.
Josh Buehler
Operating Partner
Tamarind Hill
Check: $2M-$7M seed rounds, as published by Tamarind Hill.
Josh Buehler invests or supports investments through Tamarind Hill's published strategy: Lead seed rounds for B2B healthcare companies with early product-market fit across decentralized care, care economics and healthcare supply-chain innovation.
Ben Trumbull
Managing Partner
Tamarind Hill
Check: $2M-$7M seed rounds, as published by Tamarind Hill.
Ben Trumbull invests or supports investments through Tamarind Hill's published strategy: Lead seed rounds for B2B healthcare companies with early product-market fit across decentralized care, care economics and healthcare supply-chain innovation.
Tony Petrucciani
Partner and Chief Financial Officer
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Tony Petrucciani is listed in a Partner and Chief Financial Officer capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Bob Saunders
General Partner
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Bob Saunders invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Nick Schoewe
Vice Chairman and General Partner
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Nick Schoewe invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Kevin McQuillan
General Partner
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Kevin McQuillan invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Murray Rode
General Partner
Bow Capital
Check: $5M average investment into core companies, as published by Bow Capital.
Murray Rode invests or supports investments through Bow Capital's published strategy: Back founders building AI for the physical world across modern industry, defense, logistics and digital biology, using the University of California ecosystem to accelerate science into society.
Michelle Cao
Vice President, Investments
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Michelle Cao invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Manu Sharma
Vice President, Investments
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Manu Sharma invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Kelley Quinn
Finance and Operations Manager
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Kelley Quinn is listed in a Finance and Operations Manager capacity at OCA Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Waverly Deutsch
Operating Partner
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Waverly Deutsch invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Peter Ianlo
Chairman and Co-Founder
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Peter Ianlo invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Sarah Manasevit
Senior Associate
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Sarah Manasevit invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Leticia Martinez
Senior Executive Assistant
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Leticia Martinez is listed in a Senior Executive Assistant capacity at OCA Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Kayla Liederbach
Fractional Head of Marketing
HealthX Ventures
Check: HealthX Ventures does not publish a standard check-size range on its current official website.
Kayla Liederbach contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.
Bill Trainor
Co-Founder and Partner
Mutual Capital Partners
Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.
Bill Trainor invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.
Wayne Wallace
Co-Founder and Partner
Mutual Capital Partners
Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.
Wayne Wallace invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.
Ally Thill
Project Leader
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Ally Thill is listed in a Project Leader capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Ian Drury
Venture Partner
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Ian Drury invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Dan Clark
Venture Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Dan Clark invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
David Helmer
Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
David Helmer invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Eric Beier
Partner and Chief Medical Officer
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Eric Beier invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Insoo Chang
Principal
Tau Ventures
Check: Tau Ventures does not publish a standard current check-size range on its live official site.
Insoo Chang invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.
Mark Shary
Managing Partner
Tamarind Hill
Check: $2M-$7M seed rounds, as published by Tamarind Hill.
Mark Shary invests or supports investments through Tamarind Hill's published strategy: Lead seed rounds for B2B healthcare companies with early product-market fit across decentralized care, care economics and healthcare supply-chain innovation.
Jim Dugan
Founding Managing Partner
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Jim Dugan invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Steve Shein
Principal
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Steve Shein invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
John Dugan
Chairman Emeritus and Co-Founder
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
John Dugan invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Dave Zyer
Venture Partner
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Dave Zyer invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
John Barnard
MBA Intern
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
John Barnard invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Rashika Rahman
Intern
OCA Ventures
Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.
Rashika Rahman invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.
Jim Adox
Managing Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Jim Adox invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Will Brune
Senior Associate
Mutual Capital Partners
Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.
Will Brune invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.
Mark Bakken
Managing Partner
HealthX Ventures
Check: HealthX Ventures does not publish a standard check-size range on its current official website.
Mark Bakken contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.
Samantha McGrandy
Chief Financial Officer
HealthX Ventures
Check: HealthX Ventures does not publish a standard check-size range on its current official website.
Samantha McGrandy contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.
Darcey Nett
Partner
HealthX Ventures
Check: HealthX Ventures does not publish a standard check-size range on its current official website.
Darcey Nett contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.
Linda Olson
Office Manager
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Linda Olson is listed in a Office Manager capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Funds focused on Digital Health
EquityPitcher Ventures
Zürich, Switzerland
NLC Health Ventures
Amsterdam, Netherlands
Seventure Partners
Paris, France
Innovestor
Helsinki, Finland
Ventech
Paris, Helsinki, Stockholm, Munich, Hong Kong and Shanghai
P101
Milan, Italy
Wellington Partners
Munich, Germany
Kurma Partners
Paris, France / Munich, Germany
OCA Ventures
Chicago, Illinois
Capnamic
Cologne and Berlin, Germany
HPE Growth
Amsterdam, Netherlands
nFront Ventures
Oslo, Norway and London, United Kingdom
3VC
Vienna, Austria
Define Ventures
Silicon Valley, California
Calm/Storm Ventures
Vienna, Austria
Panakès Partners
Milan, Italy
7wire Ventures
Chicago, Illinois
Boomerang Ventures
Indianapolis, Indiana
Clarevia
Madison, Wisconsin
GoHub Ventures
Valencia, Spain
Nina Capital
Barcelona, Spain
Heal Capital
Berlin, Germany
HealthX Ventures
Madison, Wisconsin
Tau Ventures
Palo Alto, California
AUM: $85M+ AUM disclosed on the firm's archived official site
Genesis Ventures
Athens, Greece
Bow Capital
Menlo Park, California
People Ventures
Copenhagen, Denmark
TEN13
Brisbane, Australia
Zero One Hundred
Bratislava, Prague, Cyprus and the UAE
Vesalius Biocapital
Luxembourg
Mutual Capital Partners
Westlake, Ohio
Rock Health Capital
San Francisco, California
Tamarind Hill
Dublin, Ohio
Healthy.Capital
Amsterdam, Netherlands
GreyMatter
United States